DE69816060D1 - Verwendung von 5ht3 antagonisten zum fördern der darmspülung - Google Patents

Verwendung von 5ht3 antagonisten zum fördern der darmspülung

Info

Publication number
DE69816060D1
DE69816060D1 DE69816060T DE69816060T DE69816060D1 DE 69816060 D1 DE69816060 D1 DE 69816060D1 DE 69816060 T DE69816060 T DE 69816060T DE 69816060 T DE69816060 T DE 69816060T DE 69816060 D1 DE69816060 D1 DE 69816060D1
Authority
DE
Germany
Prior art keywords
antagonists
colon
promote
concerned
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69816060T
Other languages
English (en)
Other versions
DE69816060T2 (de
Inventor
Adrianus Megens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE69816060D1 publication Critical patent/DE69816060D1/de
Application granted granted Critical
Publication of DE69816060T2 publication Critical patent/DE69816060T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69816060T 1997-04-18 1998-04-14 Verwendung von 5ht3 antagonisten zum fördern der darmspülung Expired - Lifetime DE69816060T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97201149 1997-04-18
EP97201149 1997-04-18
PCT/EP1998/002356 WO1998047481A1 (en) 1997-04-18 1998-04-14 Use of 5ht3 antagonists for promoting intestinal lavage

Publications (2)

Publication Number Publication Date
DE69816060D1 true DE69816060D1 (de) 2003-08-07
DE69816060T2 DE69816060T2 (de) 2004-04-22

Family

ID=8228223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816060T Expired - Lifetime DE69816060T2 (de) 1997-04-18 1998-04-14 Verwendung von 5ht3 antagonisten zum fördern der darmspülung

Country Status (12)

Country Link
US (2) US6235745B1 (de)
EP (1) EP0975327B1 (de)
JP (1) JP2001523239A (de)
KR (1) KR100529512B1 (de)
AT (1) ATE243993T1 (de)
AU (1) AU745361B2 (de)
CA (1) CA2286076C (de)
DE (1) DE69816060T2 (de)
DK (1) DK0975327T3 (de)
ES (1) ES2202855T3 (de)
PT (1) PT975327E (de)
WO (1) WO1998047481A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090638A1 (de) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Verwendung von (R)-Zacopride oder dessen Salz zur Herstellung eines Medikaments für die Behandlung von Schlafapnoe
WO2002041918A2 (en) * 2000-11-24 2002-05-30 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6946149B2 (en) * 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
JP2006503864A (ja) * 2002-10-01 2006-02-02 ジヨンソン・アンド・ジヨンソン・フアーマシユーチカル・リサーチ・アンド・デベロツプメント・インコーポレーテツド タンパク質チロシンキナーゼ阻害剤としての４，６−ジアミノ置換−２−［オキシ又はアミノキシ］−［１，３，５］トリアジン
US6996500B2 (en) * 2002-10-30 2006-02-07 Hewlett-Packard Development Company, L.P. Method for communicating diagnostic data
US20040147510A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
DE602004007225T2 (de) 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
US7049319B2 (en) * 2003-09-23 2006-05-23 Semaan Abboud Colon cleansing composition and method
JPWO2005099698A1 (ja) * 2004-04-15 2008-03-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化された４−アミノ−５−クロロ−Ｎ−［（１Ｒ，３ｒ，５Ｓ）−８−メチル−８−アザビシクロ［３．２．１］オクタ−３−イル］−２−［１−メチルブタ−２−インイルオキシ］ベンズアミド含有組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007019888A2 (en) * 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
JP2009504740A (ja) * 2005-08-16 2009-02-05 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）製剤
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
MX2009001494A (es) 2006-08-07 2009-04-23 Albany Molecular Res Inc 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
AU2014218599C1 (en) * 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
WO2014144407A1 (en) 2013-03-15 2014-09-18 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
EP3858828A4 (de) * 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited Heterocyclische verbindung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB893267A (en) 1958-11-25 1962-04-04 Sterling Drug Inc Laxative enemas
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
TW294595B (de) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
US6103734A (en) 1994-11-04 2000-08-15 Legarda Ibanez; Juan Jose Drug combination as a medicament to suppress the dependence of individuals to opiates
WO1996014071A1 (es) 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combinacion de farmacos como medicamento destinado a supresion de dependencia de individuos a opiaceos
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Also Published As

Publication number Publication date
ATE243993T1 (de) 2003-07-15
KR20000075858A (ko) 2000-12-26
KR100529512B1 (ko) 2005-11-22
AU7528298A (en) 1998-11-13
AU745361B2 (en) 2002-03-21
CA2286076A1 (en) 1998-10-29
DK0975327T3 (da) 2003-10-20
US20010020025A1 (en) 2001-09-06
EP0975327B1 (de) 2003-07-02
DE69816060T2 (de) 2004-04-22
US6555546B2 (en) 2003-04-29
JP2001523239A (ja) 2001-11-20
EP0975327A1 (de) 2000-02-02
ES2202855T3 (es) 2004-04-01
US6235745B1 (en) 2001-05-22
CA2286076C (en) 2006-12-12
PT975327E (pt) 2003-11-28
WO1998047481A1 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
DE69816060D1 (de) Verwendung von 5ht3 antagonisten zum fördern der darmspülung
TR200000782T2 (tr) Resorsinol türevleri.
ATE253073T1 (de) Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
EA199900693A1 (ru) Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
ATE274348T1 (de) Überbrückte indenopyrrolocarbazole
ITRM20010356A0 (it) "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
ATE294164T1 (de) Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening
TR200200460T2 (tr) Yeni fenilpiperazinler
AR016981A2 (es) Polipeptidos sinteticos
DE69804198T2 (de) Zementschlamm für die zementierung von bohrlöchern insbesondere ölbohrlöchern
DE69934305D1 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
DE69915486D1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
TR200103448T2 (tr) IL-8 reseptör antagonistleri.
EA200200727A1 (ru) Новые производные индола
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
PE20399A1 (es) Muteina ob
EA200500878A1 (ru) Кальцилитические соединения
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition